

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK, ss.

BOARD OF REGISTRATION
IN PHARMACY

In the Matter of)
Carie Boyd Pharmaceuticals)
License No. NO00011)
Exp: December 31, 2025)

Docket No.: PHA-2024-0145
PHA-2025-0005

CONSENT AGREEMENT FOR REPRIMAND

The Massachusetts Board of Registration in Pharmacy (Board) and Carie Boyd Pharmaceuticals (Licensee), a non-resident outsourcing facility licensed by the Board, license no. NO00011, do hereby stipulate and agree that the following information shall be entered into and become a permanent part of the Licensee's record maintained by the Board:

1. The Licensee acknowledges the Board opened complaints against its Massachusetts Non-Resident Outsourcing Facility License related to the conduct set forth in Paragraph 2, identified as Docket Numbers PHA-2024-0145 and PHA-2025-0005 (Complaints).
2. The Licensee and the Board agree to resolve these Complaints without making any admissions or findings and without proceeding to a formal adjudicatory hearing. The Complaints allege the following:

PHA-2024-0145: Effective June 25, 2024, the Ohio Board of Pharmacy (OH BOP) and the Licensee entered into an agreement for a reprimand and two-hundred and fifty dollar (\$250.00) fine based on illegal sales of dangerous drugs at wholesale to an unlicensed entity, in violation of the Ohio Revised Code. The Licensee failed to notify the Board within fourteen (14) days of the OH BOP discipline.

PHA-2025-0005: On December 17, 2024, the Food and Drug Administration issued a Warning Letter #694687 to the Licensee based on production of drug products in violation of the Federal Food, Drug, and Cosmetic Act.

3. The Board and Licensee acknowledge and agree that based upon the information described in Paragraph 2 the Board could find the Licensee in violation of 247 Code Mass. Regs. § 21.09(6) and 21 U.S.C. § 353b, warranting disciplinary action by the Board under G.L. c. 112, §§ 42A, 61 and 247 Code Mass. Regs. §§ 10.03(1)(a), (b).
4. The Licensee agrees that the Board shall impose a REPRIMAND on its license based on the facts described in Paragraph 2, effective as of the date on which the Board signs this Agreement (Effective Date).

Carie Boyd Pharmaceuticals
License No. NO00011
PHA-2024-0145 and PHA-2025-0005

5. The Board agrees that in return for the Licensee's execution and successful compliance with all the requirements of this Agreement, the Board will not prosecute the Complaints.
6. The Licensee understands that it has a right to formal adjudicatory hearing concerning the Complaint and that during said adjudication the Licensee would possess the right to confront and cross-examine witnesses, to call witnesses, to present evidence, to testify on its own behalf, to contest the allegations, to present oral argument, to appeal to the courts, and all other rights as set forth in the Massachusetts Administrative Procedures Act, G.L. c. 30A, and the Standard Adjudicatory Rules of Practice and Procedure, 801 Code Mass. Regs. § 1.01 *et seq.* The Licensee further understands that by executing this Agreement the Licensee is knowingly and voluntarily waiving its right to a formal adjudication of the Complaint.
7. The Licensee acknowledges that it has been at all times represented by Counsel or otherwise free to seek and use legal counsel in connection with the Complaint and this Agreement.
8. The Licensee acknowledges that after the Effective Date, the Agreement constitutes a public record of disciplinary action by the Board subject to the Commonwealth of Massachusetts' Public Records Law, G.L. c. 4, § 7. The Board may forward a copy of this Agreement to other licensing boards, law enforcement entities, and other individuals or entities as required or permitted by law.
9. The Licensee understands and agrees that entering into this Agreement is a voluntary and final act and not subject to reconsideration, appeal or judicial review.
10. The individual signing this Agreement certifies that they are authorized to enter into this Agreement on behalf of the Licensee, and that they have read this Agreement.

10/01/2025
Date

Jeffrey W. Crouse, PharmD
(signature)

Jeffrey W. Crouse, PharmD
(print name)

Michael J. Godek

Michael Godek, R. Ph.
Executive Director
Board of Registration in Pharmacy

10/08/2025
Effective Date

Fully Signed Agreement Sent to Licensee on October 14, 2025 by Certified Mail
No. 9589 0710 5270 1211 6896 09

Carie Boyd Pharmaceuticals
License No. NO00011
PHA-2024-0145 and PHA-2025-0005